Health Care

Neuova Holding AG appoints Joe Ghiz and Shannon Basham to lead global expansion of its tinnitus‑treatment device, boosting market reach, reimbursement deals and patient access.

Discover how Waters Corp’s decade‑long growth, strategic market access, and AI‑driven innovation keep it a top contender in the life‑science instrumentation sector.

Kyowa Kirin partners with Knight Therapeutics to launch POTELIGEO for CTCL in Latin America, offering a high‑efficacy monoclonal antibody and strong market‑access strategy.

Philips beats market volatility, boosting digital health with AI imaging and connected care, driving 7.2% revenue growth while keeping debt low and cash flow strong.

ResMed’s October 1, 2026 SEC filings reveal board changes, AI‑driven strategy, a Noctrix Health acquisition, and shareholder‑value moves.

Revolution Medicines’ recent equity moves by Alan Sandler reveal routine governance but underscore strong oncology pipeline, high‑margin prospects, and strategic alignment of exec incentives with shareholder value.

Fresenius SE completes full takeover of mAbxience, gaining 100% control over its biosimilar platform and boosting affordable biologic access.

Explore Bayer AG’s recent stock drop, legal risks, and new FDA‑accelerated therapy for menopausal hot flashes and EMA‑orphan retinal drug—what it means for investors.

UnitedHealth unveils 2027 Medicare Advantage plans with zero‑premium options, tighter networks and UCard security upgrades, reshaping senior coverage amid rising costs and a new CalPERS lawsuit.

Pfizer’s phase‑II success with tilrekimig shows promise for atopic dermatitis, while new Medicare pricing rules and value‑based contracts reshape pharma reimbursement.